Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.

Wiznia A, Stanley K, Krogstad P, Johnson G, Lee S, McNamara J, Moye J, Jackson JB, Mendez H, Aguayo R, Dieudonne A, Kovacs A, Bamji M, Abrams E, Rana S, Sever J, Nachman S.

AIDS Res Hum Retroviruses. 2000 Aug 10;16(12):1113-21.

PMID:
10954886
2.

Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.

Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, Mofenson L, Fiscus S, Rathore M, Jimenez E, Borkowsky W, Pitt J, Smith ME, Wells B, McIntosh K.

JAMA. 2000 Jan 26;283(4):492-8.

PMID:
10659875
3.

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.

Krogstad P, Lee S, Johnson G, Stanley K, McNamara J, Moye J, Jackson JB, Aguayo R, Dieudonne A, Khoury M, Mendez H, Nachman S, Wiznia A; Pediatric AIDS Clinical Trials Group 377 Study Team.

Clin Infect Dis. 2002 Apr 1;34(7):991-1001. Epub 2002 Feb 27.

4.

Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.

King JR, Nachman S, Yogev R, Hodge J, Aldrovandi G, Hughes MD, Chen J, Wiznia A, Damle B, Acosta EP.

Pediatr Infect Dis J. 2005 Oct;24(10):880-5.

PMID:
16220085
5.

Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).

Eshleman SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P.

J Infect Dis. 2001 Jun 15;183(12):1732-8. Epub 2001 May 16.

6.

Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).

Lowe SH, Wensing AM, Hassink EA, ten Kate RW, Richter C, Schreij G, Koopmans PP, Juttmann JR, van der Tweel I, Lange JM, Borleffs JC.

HIV Clin Trials. 2005 Sep-Oct;6(5):235-45.

PMID:
16306030
7.

A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).

Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J.

Antivir Ther. 2002 Jun;7(2):81-90.

PMID:
12212928
8.

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E; M98-863 Study Team.

N Engl J Med. 2002 Jun 27;346(26):2039-46.

9.

A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients.

Smith D, Hales G, Roth N, Law M, Ray J, Druett J, Mitchell J, Mills G, Doong N, Franklin R; CHRN 025 Study Group. Community HIV Research Network.

HIV Clin Trials. 2001 Mar-Apr;2(2):97-107.

PMID:
11590517
10.

Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.

Casado JL, Dronda F, Hertogs K, Sabido R, Antela A, Martí-Belda P, Dehertogh P, Moreno S; NELSANE Study.

AIDS Res Hum Retroviruses. 2001 Jan 20;17(2):93-8.

PMID:
11177388
11.

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, Gu K, Hsu A, Brun S, Sun E.

J Infect Dis. 2004 Jan 1;189(1):51-60. Epub 2003 Dec 31.

12.

Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.

Fletcher CV, Yogev R, Nachman SA, Wiznia A, Pelton S, McIntosh K, Stanley K.

Pharmacotherapy. 2004 Apr;24(4):453-9.

PMID:
15098798
13.

Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland.

Nadal D, Steiner F, Cheseaux JJ, Lazarevitch CA, Aebi C, Kind C, Rudin C.

Infection. 2000 Sep;28(5):287-96. Erratum in: Infection 2000 Nov-Dec;28(6):402.

PMID:
11073135
14.

A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.

Kirk O, Lundgren JD, Pedersen C, Mathiesen LR, Nielsen H, Katzenstein TL, Obel N, Gerstoft J.

Antivir Ther. 2003 Dec;8(6):595-602.

PMID:
14760893
15.

The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study.

Jensen-Fangel S, Thomsen HF, Larsen L, Black FT, Obel N.

J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):124-9.

PMID:
11404533
16.

Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.

Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, Hunt G, Hu CC, Tsai WY, Morris L, Kuhn L.

JAMA. 2010 Sep 8;304(10):1082-90. doi: 10.1001/jama.2010.1278.

17.

Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.

Siegfried NL, Van Deventer PJ, Mahomed FA, Rutherford GW.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004535. Review.

PMID:
16625606
18.

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.

Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, Patterson P, Sierra Madero J, Sued O, Figueroa MI, Rolon MJ; GARDEL Study Group.

Lancet Infect Dis. 2014 Jul;14(7):572-80. doi: 10.1016/S1473-3099(14)70736-4. Epub 2014 Apr 27.

PMID:
24783988
19.

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).

Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1591-600.

PMID:
10983646
20.

Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.

Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fätkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H.

AIDS. 2000 Jun 16;14(9):1181-5.

PMID:
10894282
Items per page

Supplemental Content

Write to the Help Desk